» Articles » PMID: 12388637

Angiotensin II Increases Expression of Cyclooxygenase-2: Implications for the Function of Vascular Smooth Muscle Cells

Overview
Specialty Pharmacology
Date 2002 Oct 22
PMID 12388637
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

In vascular smooth muscle, increased expression of cyclooxygenase-2 (COX-2) has emerged as an important mechanism for regulation of prostanoid synthesis influenced by vessel injury, cytokines, and growth factors. We have investigated how COX-2 participates in angiotensin II (ANG II)-mediated cell responses in cultured human vascular smooth muscle cells (VSMCs). ANG II type 1 (AT1) receptors induce increased accumulation of COX-2, both at the mRNA and protein levels. ANG II increased transcription of the COX-2 gene; also, nuclear extracts from stimulated cells had increased NF-kappa B binding to its DNA consensus sequence. ANG II-induced COX-2 expression was markedly blunted by inhibition of mitogen-activated protein kinase. Furthermore, the ANG II-induced increase in COX-2 protein abundance was attenuated by both the peroxisome proliferator-activated receptor alpha (PPARalpha) activator Wy-14,643 [pyrinixic acid; 4-chloro-6-(2,3-xylidino)-2-pyrimidinyl) thioacetic acid] and the PPARgamma activator 15d-PGJ2 (15-deoxy-Delta(12-14)-prostaglandin J2). Not only did ANG II increase COX-2 expression and prostaglandin synthesis, ANG II-stimulated DNA synthesis and cell migration were dependent on COX-2 activity. PPARalpha and PPARgamma activators inhibited ANG II-stimulated DNA synthesis and cell migration. These results suggest that ANG II enhances COX-2 expression at the transcription level; also, COX-2 activity plays an important role in mediating ANG II- induced proliferation and migration of VSMCs, suggesting the possibility of magnification of ANG II effects over time due to the induction of COX-2 expression. These results also demonstrate that both the alpha and gamma type of PPAR activators inhibit COX-2 expression induced by angiotensin II in VSMCs which may have therapeutic significance in vascular diseases.

Citing Articles

Chronic Low-Level Lead Exposure Increases Mesenteric Vascular Reactivity: Role of Cyclooxygenase-2-Derived Prostanoids.

Simoes M, Azevedo B, Alonso M, Salaices M, Vassallo D Front Physiol. 2021; 11:590308.

PMID: 33488395 PMC: 7818781. DOI: 10.3389/fphys.2020.590308.


Angiotensin II-Regulated Autophagy Is Required for Vascular Smooth Muscle Cell Hypertrophy.

Mondaca-Ruff D, Riquelme J, Quiroga C, Norambuena-Soto I, Sanhueza-Olivares F, Villar-Fincheira P Front Pharmacol. 2019; 9:1553.

PMID: 30804791 PMC: 6371839. DOI: 10.3389/fphar.2018.01553.


Correlations between gene expression highlight a different activation of ACE/TLR4/PTGS2 signaling in symptomatic and asymptomatic plaques in atherosclerotic patients.

Ferronato S, Scuro A, Gomez-Lira M, Mazzucco S, Olivato S, Turco A Mol Biol Rep. 2018; 45(4):657-662.

PMID: 29923152 DOI: 10.1007/s11033-018-4207-7.


EPA:DHA 6:1 prevents angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase- and COX-derived oxidative stress.

Rasul Niazi Z, Silva G, Porto Ribeiro T, Leon-Gonzalez A, Kassem M, Mirajkar A Hypertens Res. 2017; 40(12):966-975.

PMID: 28878301 DOI: 10.1038/hr.2017.72.


Gene expression profiles and signaling mechanisms in α-adrenoceptor-evoked proliferation of vascular smooth muscle cells.

Huhtinen A, Hongisto V, Laiho A, Loyttyniemi E, Pijnenburg D, Scheinin M BMC Syst Biol. 2017; 11(1):65.

PMID: 28659168 PMC: 5490158. DOI: 10.1186/s12918-017-0439-8.